Gene Therapy for Muscular Dystrophy: Elevidys, Trials, and What Families Need to Know

When a child is diagnosed with Duchenne muscular dystrophy, the world changes in an instant. Parents learn that their son — because it is almost always a son — has a progressive, incurable muscle-wasting disease that will likely confine him to a wheelchair by his early teens and threaten his life by his twenties or thirties. For decades, there was no treatment that addressed the root cause. Steroids slowed the decline, physical therapy preserved function a little longer, and cardiac medications extended life — but nothing stopped the relentless loss of muscle.

Then came gene therapy. In June 2023, the FDA approved Elevidys (delandistrogene moxeparvovec), the first gene therapy for Duchenne muscular dystrophy. It was a moment of enormous hope — and enormous controversy. The advisory committee had voted against approval. The price was set at $3.2 million. The clinical data was, to put it diplomatically, complicated.

This article is written for families, patients, and anyone trying to understand where gene therapy for DMD stands in 2026 — what works, what doesn't, what's coming next, and what questions you should be asking. We'll be honest about the science, because families deserve honesty more than hype.

What Is Duchenne Muscular Dystrophy?

Duchenne muscular dystrophy (DMD) is a severe genetic disorder that causes progressive muscle degeneration and weakness. It is one of the most common fatal genetic diseases diagnosed in childhood, affecting approximately 1 in 3,500 to 5,000 male births worldwide. That translates to roughly 10,000 to 15,000 boys and young men living with DMD in the United States, and an estimated 300,000 worldwide.

The Genetic Cause

DMD is caused by mutations in the DMD gene, located on the X chromosome. This gene provides instructions for making a protein called dystrophin, which acts as a molecular shock absorber for muscle fibers. Dystrophin sits just beneath the cell membrane of muscle cells, connecting the internal structural framework (the cytoskeleton) to the extracellular matrix outside the cell. Every time a muscle contracts, dystrophin absorbs and distributes the mechanical stress, protecting the cell membrane from tearing.

In boys with DMD, mutations — most often large deletions — disrupt the reading frame of the DMD gene, meaning the cell cannot produce any functional dystrophin at all. Without this critical protein, muscle fibers are damaged with every contraction. The body tries to repair the damage, but over time the repair mechanisms are overwhelmed. Muscle tissue is progressively replaced by scar tissue and fat, and the muscles weaken irreversibly.

Why Boys Are Affected

DMD follows an X-linked recessive inheritance pattern. Because boys have only one X chromosome (XY), a single mutated copy of the DMD gene is enough to cause the disease. Girls, who have two X chromosomes (XX), are typically carriers — their second, functional copy of the gene compensates. About one-third of DMD cases arise from new (de novo) mutations, meaning there is no family history.

Some female carriers do experience mild symptoms, including muscle weakness and cardiac involvement, and should be monitored. But the severe, classic presentation of DMD occurs almost exclusively in males.

The Clinical Course

The trajectory of DMD is painfully predictable:

• Ages 2-5: Early signs appear — delayed walking, difficulty running, frequent falls, trouble climbing stairs. A hallmark sign is Gowers' maneuver, where a child uses their hands to "walk up" their own legs when rising from the floor.
• Ages 6-12: Muscle weakness progresses. Walking becomes increasingly difficult. Most boys transition to a wheelchair between ages 10 and 13.
• Ages 13-20: Upper body strength declines. Scoliosis often develops. Respiratory function deteriorates as the muscles that control breathing weaken.
• Ages 20+: Cardiac and respiratory complications become the primary threat. With modern supportive care — including corticosteroids, cardiac medications, and assisted ventilation — many patients now survive into their thirties or beyond. Decades ago, survival past the mid-twenties was rare.

It is worth emphasizing: DMD is not a cognitive disease. Boys with Duchenne have the same range of intelligence, humor, ambition, and personality as anyone else. Some do experience learning differences or behavioral challenges linked to brain-expressed dystrophin isoforms, but the defining feature of the disease is progressive skeletal and cardiac muscle loss.

Becker Muscular Dystrophy: The Milder Cousin

A closely related condition, Becker muscular dystrophy (BMD), is caused by mutations in the same DMD gene — but these mutations preserve the reading frame, allowing the cell to produce a shortened but partially functional version of dystrophin. Because some dystrophin is present, Becker MD is milder: onset is later, progression is slower, and many patients remain ambulatory into their forties or beyond. Some individuals with Becker MD live near-normal lifespans.

The distinction between Duchenne and Becker is crucial to understanding the gene therapy approach. If you can convert a Duchenne-type mutation (no dystrophin) into something that looks more like a Becker-type mutation (some dystrophin), you might transform a devastating disease into a manageable one. That insight drives almost every DMD gene therapy strategy in development today.

The Dystrophin Challenge: Why Gene Therapy for DMD Is So Hard

If DMD is caused by a missing protein, why not just deliver a working copy of the gene? That is exactly the idea behind gene therapy — but DMD presents a uniquely difficult engineering problem.

The Biggest Gene in the Human Genome

The DMD gene is enormous. Its coding sequence (the mRNA) spans about 14,000 base pairs, and the full genomic locus stretches across 2.4 million base pairs (2.4 Mb) of DNA on the X chromosome — making it the largest known gene in the human genome. By comparison, most human genes are a few thousand base pairs.

This matters because the workhorse delivery vehicle for gene therapy — adeno-associated virus (AAV) — can only carry a DNA payload of approximately 4,700 base pairs (4.7 kb). The full dystrophin coding sequence is roughly three times larger than what an AAV vector can hold. You simply cannot fit it in.

This size constraint has shaped the entire field. Researchers have pursued three main strategies to work around it.

Strategy 1: Micro-Dystrophin (The Elevidys Approach)

The most advanced approach takes inspiration from Becker muscular dystrophy. Researchers engineered a micro-dystrophin gene — a radically shortened version of dystrophin that retains the most critical functional domains while being small enough to fit inside an AAV capsid.

Think of dystrophin as a long rod with hooks at each end — one end anchors to the inside of the cell, the other to proteins on the cell surface. The middle of the rod consists of 24 spectrin-like repeats that act as a flexible spacer. By deleting most of these central repeats (keeping just 4 or 5), researchers created a protein that is roughly one-third the size of native dystrophin but still connects the cytoskeleton to the extracellular matrix.

This micro-dystrophin is not as good as the real thing. It lacks many of the interaction sites that full-length dystrophin uses to recruit signaling proteins, nitric oxide synthase, and other partners. But the theory is compelling: even a truncated scaffold should protect muscle fibers from contraction-induced damage, slowing or halting the cycle of degeneration.

Strategy 2: Exon Skipping

Rather than delivering a new gene, exon skipping uses antisense oligonucleotides (small synthetic molecules) to trick the cell's splicing machinery into "skipping" the mutated exon during mRNA processing. This restores the reading frame, allowing the cell to produce a shorter but partially functional dystrophin — essentially converting Duchenne into Becker at the RNA level.

Several exon-skipping drugs have been approved under accelerated pathways: Exondys 51 (eteplirsen, targeting exon 51), Vyondys 53 (golodirsen, exon 53), Viltepso (viltolarsen, exon 53), and Amondys 45 (casimersen, exon 45). These each apply to a subset of patients depending on their specific mutation.

The catch: exon-skipping drugs must be administered weekly by intravenous infusion, they produce very modest amounts of dystrophin (typically 1-5% of normal levels), and their clinical benefit has been debated. The FDA granted accelerated approval based on the surrogate endpoint of dystrophin production, but confirmatory trials showing functional benefit have been mixed. These treatments remain controversial.

Strategy 3: CRISPR Gene Editing

The newest and most ambitious approach uses CRISPR-Cas9 to permanently edit the DMD gene within muscle cells. Rather than delivering a miniaturized gene or a temporary RNA patch, CRISPR can delete the mutated exon(s) directly from the genome, restoring the reading frame at the DNA level and allowing the cell to produce Becker-like dystrophin permanently from its own gene.

This is still in preclinical and early clinical stages for DMD, and we will return to it later. But it represents the theoretical ideal: a one-time treatment that converts Duchenne to Becker at the genomic level, with the cell producing its own truncated dystrophin indefinitely.

Elevidys: The First Gene Therapy for DMD

What It Is

Elevidys (delandistrogene moxeparvovec), developed by Sarepta Therapeutics, is a one-time intravenous gene therapy that delivers a micro-dystrophin transgene using an AAV vector (specifically, AAVrh74 — a rhesus macaque-derived serotype with strong tropism for skeletal and cardiac muscle).

The micro-dystrophin cassette used in Elevidys encodes a protein containing spectrin-like repeats 1-3 and 24, plus the critical N-terminal and C-terminal domains and hinge regions needed for structural function. It is driven by a muscle-specific promoter (MHCK7) to ensure expression primarily in skeletal and cardiac muscle.

The therapy is administered as a single intravenous infusion, typically over one to two hours. The AAV particles distribute throughout the body and transduce muscle cells, which then begin producing micro-dystrophin.

Approval History: A Contentious Path

Elevidys' road to approval was one of the most contentious in recent FDA history.

May 2023: An FDA advisory committee reviewed Sarepta's application and voted 8-6 against approval, citing insufficient evidence that micro-dystrophin expression translated into meaningful clinical benefit. The committee noted that while biopsy data showed increased micro-dystrophin in treated patients, the primary functional endpoint in the pivotal EMBARK trial — the North Star Ambulatory Assessment (NSAA) — had not reached statistical significance at the pre-specified time point.

June 2023: Despite the advisory committee's vote, the FDA granted accelerated approval for Elevidys in ambulatory patients aged 4 to 5 years. The agency determined that micro-dystrophin expression was a reasonably likely surrogate endpoint and that the unmet medical need was severe enough to justify approval while confirmatory data was gathered.

June 2024: The FDA expanded the indication to include all ambulatory patients aged 4 years and older, removing the upper age restriction. This decision was based on additional data from the EMBARK trial and the broader Sarepta clinical program.

Key context for families: Accelerated approval means the drug can be sold while Sarepta continues to gather confirmatory evidence that micro-dystrophin expression actually leads to functional improvement. If confirmatory trials fail to demonstrate clinical benefit, the FDA could theoretically withdraw approval — though this is rare.

The EMBARK Trial: What the Data Shows

The EMBARK trial (Study SRP-9001-301) was a randomized, double-blind, placebo-controlled study — the gold standard for clinical evidence. It enrolled 125 ambulatory boys with DMD, aged 4 to 7, who were randomized to receive either Elevidys or placebo.

The primary endpoint — the NSAA score at 52 weeks — was not met. The treated group improved by an average of 2.6 points on the NSAA compared to 1.9 points for placebo, a difference that was not statistically significant (p = 0.37).

However, Sarepta highlighted several secondary and exploratory endpoints:

• Micro-dystrophin expression: Muscle biopsies at 12 weeks showed a mean expression of approximately 30-55% of normal dystrophin levels in treated patients, compared to less than 1% at baseline. This was the basis for accelerated approval.
• Time to rise from floor: Treated patients showed a statistically significant improvement in timed function tests, including time to rise from the floor.
• Subgroup analyses: Some subgroups appeared to show greater benefit, including younger patients.
• Longer follow-up: At two and three years, treated patients appeared to maintain functional stability while natural history data suggested continued decline would be expected in untreated patients.

What critics say: Missing the primary endpoint in a well-designed trial is significant. Subgroup analyses and exploratory endpoints can generate hypotheses but do not constitute proof of efficacy. The natural history comparisons used by Sarepta relied on external control groups rather than the randomized placebo arm, which introduces bias.

What supporters say: DMD is a slowly progressive disease, and 52 weeks may not be enough time to see functional divergence — especially in young patients who are still gaining function. Micro-dystrophin expression is biologically plausible as a predictor of long-term benefit, and the functional trends are consistent with slowing of disease progression.

The honest answer is that we do not yet know with certainty whether Elevidys provides meaningful, lasting functional benefit. The data is suggestive but not definitive. This is the fundamental tension of accelerated approval in devastating diseases: families cannot wait for perfect data, but neither should they be given false certainty.

The Price: $3.2 Million

Elevidys carries a list price of $3.2 million, making it one of the most expensive therapies in the world. Sarepta has argued that this reflects the one-time nature of the treatment, the severity of the disease, the high cost of lifetime care for DMD patients (estimated at $1-2 million or more), and the small patient population.

Most commercial insurance plans and Medicaid programs have negotiated coverage, often with outcomes-based agreements where Sarepta provides rebates if the therapy does not meet certain milestones. Sarepta has also established a patient assistance program.

For families, the financial burden extends beyond the drug price. Treatment requires hospitalization, pre-treatment testing, immunosuppression (typically prednisone for several months to manage the immune response to the AAV vector), and extensive follow-up monitoring. Out-of-pocket costs vary enormously depending on insurance.

Revenue and Market Trajectory

Elevidys generated approximately $898 million in net revenue for Sarepta in fiscal year 2025 — a remarkable commercial performance for a gene therapy targeting a rare disease. However, analysts have noted a declining trajectory in quarterly revenue, attributed to the initial bolus of pent-up demand being served and the limited pool of eligible patients.

This raises a structural challenge for all rare disease gene therapies: if the treatment is truly one-time and the patient population is small, revenue will inevitably decline after the initial cohort is treated. This economic reality has implications for long-term investment in the field and for the development of next-generation therapies.

Safety Concerns

All gene therapies carry risk, and Elevidys is no exception. The safety profile is a critical consideration for families.

Immune reactions: Because Elevidys uses an AAV vector, the patient's immune system can mount a response to the viral capsid proteins. This is why patients receive immunosuppressive therapy (typically corticosteroids) before and after infusion. Immune reactions can include elevated liver enzymes (transaminitis), fever, and vomiting. Most are manageable, but they require close monitoring.

Myocarditis signals: There have been reports of myocarditis (inflammation of the heart muscle) in patients treated with Elevidys and similar AAV-based therapies. Given that DMD itself causes progressive cardiomyopathy, distinguishing treatment-related cardiac inflammation from disease progression is challenging but critically important. Cardiac monitoring (echocardiograms, troponin levels, cardiac MRI) is a standard part of post-treatment follow-up.

Thrombotic microangiopathy (TMA): High-dose AAV infusions have been associated with TMA — a serious condition involving blood clots in small vessels, which can damage the kidneys and other organs. Cases have been reported in AAV gene therapy programs across multiple diseases.

Deaths potentially linked to viral vector exposure: Across the broader landscape of AAV gene therapy (not specific to Elevidys alone), there have been patient deaths in high-dose AAV programs, including in trials for X-linked myotubular myopathy (ASPIRO trial) and other neuromuscular diseases. These deaths, often linked to hepatotoxicity or TMA in patients with pre-existing liver compromise, have prompted the field to reconsider dosing strategies and patient selection criteria.

In the Elevidys clinical program specifically, serious adverse events have included acute liver injury, myocarditis, and immune-mediated reactions. Sarepta and the FDA have implemented a Risk Evaluation and Mitigation Strategy (REMS) that requires prescribers and treatment centers to be specially certified.

What families should know: Gene therapy is not risk-free. The potential benefits must be weighed against real risks, and the decision should be made in close consultation with a neuromuscular specialist who understands both DMD and gene therapy. Any child receiving Elevidys needs careful monitoring for weeks to months after infusion.

Other DMD Therapies in Development

Elevidys is the first but will not be the last. Several other approaches are in various stages of development.

SGT-003 (Solid Biosciences)

Solid Biosciences is developing SGT-003, a next-generation micro-dystrophin gene therapy using a novel AAV capsid (AAV-SLB101) designed to have improved muscle tropism and lower immunogenicity compared to naturally occurring AAV serotypes. SGT-003 uses a different micro-dystrophin construct than Elevidys, incorporating five spectrin-like repeats (including the critical nNOS-binding domain, repeats 16-17) that are absent from Sarepta's construct.

The inclusion of the nNOS-binding domain is potentially significant. Neuronal nitric oxide synthase (nNOS) is normally recruited to the muscle cell membrane by dystrophin, where it produces nitric oxide — a molecule critical for regulating blood flow to working muscles. The absence of nNOS signaling in DMD contributes to exercise-induced muscle fatigue and damage. If SGT-003's micro-dystrophin can restore nNOS localization, it might provide functional benefits that Elevidys cannot.

SGT-003 is currently in clinical trials, with early data expected to read out over the coming years.

Exon-Skipping Therapies (Approved and In Development)

As mentioned above, four exon-skipping drugs are already on the market:

• Exondys 51 (eteplirsen) — Sarepta, targets exon 51 (~13% of DMD patients)
• Vyondys 53 (golodirsen) — Sarepta, targets exon 53 (~8%)
• Viltepso (viltolarsen) — NS Pharma, targets exon 53 (~8%)
• Amondys 45 (casimersen) — Sarepta, targets exon 45 (~8%)

Together, these therapies are applicable to roughly 30% of DMD patients, depending on mutation type. Next-generation exon-skipping approaches aim to expand the range of treatable mutations and improve dystrophin production levels. Peptide-conjugated antisense oligonucleotides, which are designed to penetrate muscle cells more efficiently, are showing promise in preclinical studies and early trials.

Key limitation: Exon skipping is not a one-time treatment. These drugs must be administered weekly (typically by IV infusion) for the rest of the patient's life, and the dystrophin levels they produce are generally low.

CRISPR-Based Approaches for DMD

CRISPR gene editing represents the most exciting — and earliest-stage — frontier for DMD treatment. The concept is elegant: rather than delivering an artificial mini-gene or patching the RNA, use CRISPR to edit the patient's own DMD gene, deleting or correcting the problematic exon(s) to restore the reading frame.

The exon-deletion strategy: For the roughly 60-70% of DMD patients whose mutations involve one or more exons in the deletion hotspot (exons 45-55), CRISPR can be used to delete additional exons to restore the reading frame. For example, if a patient is missing exon 50, CRISPR could delete exon 51 as well, creating a shortened but in-frame gene that produces a Becker-like truncated dystrophin. This is conceptually equivalent to exon skipping but operates at the DNA level — making the change permanent rather than requiring lifelong drug infusions.

Preclinical progress: Multiple academic groups and biotech companies have demonstrated successful CRISPR-mediated exon deletion in mouse models of DMD, in human induced pluripotent stem cells (iPSCs), and in patient-derived muscle cells. Dystrophin expression is restored, and muscle function improves in animal models.

The delivery challenge: The biggest obstacle to clinical translation is delivery. CRISPR components (the Cas9 protein and guide RNAs) must reach a substantial proportion of the body's muscle cells — including the heart — to produce a meaningful clinical effect. Muscle constitutes roughly 40% of body mass, making it one of the most challenging tissues to transduce comprehensively. Current AAV-based delivery can transduce muscle but may require high doses that increase the risk of immune reactions and toxicity.

Key players: Several groups are working toward clinical CRISPR programs for DMD, including academic labs at UT Southwestern (Dr. Eric Olson's group, which pioneered the exon-deletion approach), Duke University, and companies exploring next-generation delivery platforms. As of early 2026, no CRISPR-based DMD therapy has entered pivotal clinical trials, but IND-enabling studies are underway.

The promise: If delivery challenges can be overcome, CRISPR offers the theoretical ideal: a one-time treatment that permanently converts Duchenne to Becker by editing the patient's own genome. Unlike micro-dystrophin gene therapy, the edited gene would be under native regulatory control and would produce dystrophin in the correct tissues at physiologically appropriate levels.

Utrophin Upregulation

An entirely different strategy bypasses dystrophin altogether. Utrophin is a protein closely related to dystrophin that is naturally present in developing muscle but is largely replaced by dystrophin after birth. Small molecule drugs that upregulate utrophin production could, in theory, compensate for the absence of dystrophin. Summit Therapeutics and others have explored this approach, though clinical progress has been slow.

Combination Approaches

The future of DMD treatment likely lies in combinations: gene therapy or CRISPR editing to provide structural protection, combined with anti-inflammatory agents, anti-fibrotic drugs (to address scar tissue already present), and cardiac-targeted therapies. No single approach may be sufficient for patients who have already experienced significant muscle damage by the time of treatment.

What Families Need to Know

If your child has been diagnosed with DMD, or if you are considering gene therapy, here is practical guidance based on the current landscape.

Treatment Centers

Elevidys is only available through certified treatment centers that participate in the REMS program. These are typically major academic medical centers with specialized neuromuscular clinics. As of early 2026, there are approximately 60-80 certified sites in the United States. Your neuromuscular specialist can help identify the closest center and coordinate the referral.

Key treatment centers include programs at Nationwide Children's Hospital (Columbus, OH), UCLA, Washington University in St. Louis, Children's Hospital of Philadelphia, and others. The Parent Project Muscular Dystrophy (PPMD) organization maintains a list of certified centers and can help families navigate access.

Timing Matters

One of the most important decisions is when to pursue gene therapy. Several factors make earlier treatment generally preferable:

• Muscle damage is irreversible. Gene therapy can only protect muscle that is still present. It cannot regenerate muscle that has already been replaced by scar tissue and fat. This is why the approved indication emphasizes ambulatory patients — they still have functional muscle to protect.
• Immune response to AAV. Many people develop antibodies to AAV serotypes through natural exposure. Pre-existing antibodies can neutralize the viral vector before it reaches muscle cells, rendering the therapy ineffective. Younger children are less likely to have pre-existing antibodies. All patients are tested for AAV antibody titers before treatment, and those with high titers may be ineligible.
• One-shot opportunity. With current AAV technology, gene therapy can typically be given only once. After the first exposure, the immune system develops a robust antibody response that will neutralize any subsequent dose of the same AAV serotype. This means the decision of when to treat is also the decision of which therapy to use — there may not be a second chance with the same vector.

That said, "earlier" does not mean "immediately." The optimal window depends on the individual child's clinical status, AAV antibody titers, mutation type, and the evolving landscape of available therapies. This is a conversation to have with a neuromuscular specialist, not a decision to make based on urgency alone.

Eligibility

As of early 2026, Elevidys is approved for ambulatory patients aged 4 and older with a confirmed DMD mutation. Key eligibility considerations include:

• Confirmed genetic diagnosis of DMD (typically by next-generation sequencing or multiplex ligation-dependent probe amplification)
• Ambulatory status (able to walk)
• AAV antibody titers below the threshold set by the prescribing information
• Adequate liver and kidney function
• No active infection
• Ability to tolerate immunosuppression (corticosteroids)

Patients who are non-ambulatory (wheelchair-bound) are currently not included in the approved indication, though clinical investigations in this population are ongoing.

Questions to Ask Your Doctor

If you are considering gene therapy for your child, here are questions worth asking:

1. Is my child eligible for Elevidys, and is this the right time? Eligibility depends on age, ambulatory status, AAV antibody status, and clinical condition.
2. What are the realistic expected benefits? Be wary of anyone who promises dramatic improvement. The evidence suggests possible stabilization or slowing of decline, not reversal.
3. What are the risks specific to my child? Cardiac status, liver function, and immune profile all affect the risk-benefit calculation.
4. Are there clinical trials my child might qualify for? Newer therapies (SGT-003, CRISPR approaches) may offer advantages, and trial participation provides access to cutting-edge treatments plus intensive monitoring.
5. What is the post-treatment monitoring plan? Expect frequent lab work, cardiac imaging, and clinical assessments for at least the first year.
6. What happens to other treatments? Corticosteroids and other DMD medications are typically continued after gene therapy. Gene therapy is not a replacement for comprehensive DMD care.
7. If we wait, what other options might become available? This is the hardest question. Waiting risks further muscle loss, but future therapies may be more effective.

Clinical Trials: How to Find Them

The Parent Project Muscular Dystrophy (PPMD) at parentprojectmd.org is the single best resource for families. They maintain a comprehensive clinical trial finder, educational resources, and a community of families navigating the same decisions.

ClinicalTrials.gov is the official registry of trials. Searching for "Duchenne muscular dystrophy" will return all active and recruiting studies, which can be filtered by location, age, and intervention type.

The Muscular Dystrophy Association (MDA) at mda.org also provides resources, including a network of care centers, summer camps, and advocacy support.

Insurance and Financial Assistance

Navigating insurance coverage for a $3.2 million therapy is daunting. Key points:

• Most major commercial insurers have established coverage policies for Elevidys, though prior authorization and specific criteria apply.
• Medicaid coverage varies by state but is generally available for eligible patients.
• Sarepta's SareptAssist program provides financial counseling, insurance navigation, and copay assistance.
• Outcomes-based contracts: Some payers have negotiated agreements with Sarepta where the price is adjusted based on whether the patient achieves certain clinical milestones — an innovative model that aligns cost with value.

No family should assume they cannot access treatment because of cost. Start the conversation with your care team and Sarepta's patient services early.

The Future: What Comes Next

The approval of Elevidys is a beginning, not an endpoint. The next decade will likely bring transformative advances in DMD gene therapy.

Next-Generation AAV Vectors

Engineered AAV capsids designed through directed evolution and machine learning are showing dramatically improved muscle tropism and reduced immunogenicity in preclinical studies. These next-gen vectors could allow lower doses (reducing toxicity), better cardiac transduction, and potentially even re-dosing strategies that circumvent pre-existing immunity.

Companies like Solid Biosciences, Dyno Therapeutics, and others are investing heavily in capsid engineering. The goal is a vector that reaches muscle more efficiently, avoids the liver (where AAV tends to accumulate, causing toxicity), and evades neutralizing antibodies.

Larger Transgene Capacity

Dual-AAV strategies — splitting the micro-dystrophin gene across two AAV vectors that recombine inside the cell — could allow delivery of a larger, more functional dystrophin construct. This approach is technically challenging but has shown proof of concept in animal models. A larger dystrophin protein could retain more of the interaction domains lost in current micro-dystrophin designs, potentially providing greater functional benefit.

CRISPR Moving Toward the Clinic

As CRISPR delivery technology matures and non-viral delivery platforms (lipid nanoparticles, virus-like particles) improve their ability to reach muscle tissue, CRISPR-based DMD therapies will move from preclinical studies toward clinical trials. The advantage of CRISPR — permanent, endogenous dystrophin production under native genetic control — makes it theoretically superior to transgene delivery, and the field is working rapidly to overcome the remaining technical barriers.

Combination Therapy Paradigm

The DMD community is increasingly recognizing that no single therapy will be sufficient for most patients. A boy who receives gene therapy at age 5 still has years of residual muscle damage from the years before treatment. Future care may involve:

• Gene therapy (micro-dystrophin or CRISPR) as the structural backbone
• Anti-fibrotic agents to reduce existing scar tissue
• Anti-inflammatory drugs to tamp down chronic inflammation
• Cardiac-targeted therapies to protect the heart specifically
• Rehabilitation strategies optimized for the gene therapy era

This combination paradigm is already being discussed in the research community, and clinical trials exploring multi-modal treatment are being designed.

Non-Ambulatory Patients

One of the most urgent unmet needs is treatment for non-ambulatory patients — older boys and young men who have already lost the ability to walk. Current gene therapy trials have focused on ambulatory patients, partly because it is easier to measure functional improvement in patients who can still walk, and partly because these patients have more muscle remaining to protect.

But non-ambulatory patients have the greatest need. Research into cardiac-targeted gene therapy, respiratory muscle protection, and upper-limb function preservation is critically important. Some clinical investigations are beginning to include non-ambulatory cohorts, and the community is advocating vigorously for expanded access.

A Note on Hope and Honesty

Writing about gene therapy for DMD requires holding two truths at once. The first is that this is real, meaningful progress. A decade ago, there was no gene therapy for DMD at any stage. Today, there is an approved treatment, multiple candidates in the pipeline, and a CRISPR approach that could fundamentally change the disease. Families living with DMD today have more reason for hope than at any point in history.

The second truth is that we are not there yet. Elevidys' clinical data is imperfect. The treatment is expensive, invasive, and carries real risks. It does not cure DMD — it delivers a truncated protein that may slow progression but cannot restore lost muscle. The CRISPR therapies that might do better are still years from approval.

Families deserve to know both truths. They deserve access to the best current treatments and honest information about what those treatments can and cannot do. They deserve to be included in decisions about their child's care, armed with real data rather than marketing materials.

The DMD community — families, clinicians, researchers, and advocates — has driven every advance in this field. That community's insistence on urgency, combined with its demand for rigor, is the engine that will carry gene therapy from its current, imperfect state to the transformative therapies that boys with Duchenne deserve.

---

Key Takeaways

• DMD is caused by the absence of dystrophin, a protein critical for muscle integrity, due to mutations in the largest gene in the human genome.
• Elevidys delivers a micro-dystrophin gene via AAV, was approved under accelerated approval in 2023, and expanded to ages 4+ in 2024. It costs $3.2 million.
• Clinical data showed increased micro-dystrophin expression but missed the primary functional endpoint. Benefit remains plausible but unproven by the highest evidentiary standard.
• Safety concerns include immune reactions, myocarditis signals, liver toxicity, and the one-shot nature of AAV-based therapy.
• Alternative approaches include exon skipping (approved, limited efficacy), CRISPR gene editing (preclinical, high potential), and next-gen micro-dystrophin therapies.
• Families should work with a neuromuscular specialist, understand both benefits and risks, explore clinical trials, and connect with advocacy organizations.

---

Sources and Further Reading

1. Duan, D., Goemans, N., Takeda, S., et al. "Duchenne muscular dystrophy." Nature Reviews Disease Primers, 7, 13 (2021). doi.org/10.1038/s41572-021-00248-3

2. Mendell, J.R., Sahenk, Z., Lehman, K., et al. "Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial." JAMA Neurology, 77(9), 1122-1131 (2020). doi.org/10.1001/jamaneurol.2020.1484

3. U.S. Food and Drug Administration. "FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy." FDA News Release, June 22, 2023. fda.gov

4. Sarepta Therapeutics. "EMBARK Trial Results and Elevidys Prescribing Information." sarepta.com

5. Parent Project Muscular Dystrophy. "Duchenne Gene Therapy Resource Center." parentprojectmd.org

6. Olson, E.N. "Toward the correction of muscular dystrophy by gene editing." Proceedings of the National Academy of Sciences, 118(22), e2004840117 (2021). doi.org/10.1073/pnas.2004840117

7. Solid Biosciences. "SGT-003 Program Overview." solidbio.com

8. Muscular Dystrophy Association. "Duchenne Muscular Dystrophy (DMD)." mda.org

9. ClinicalTrials.gov. Search: "Duchenne muscular dystrophy gene therapy." clinicaltrials.gov

10. Chemello, F., Bassel-Duby, R., and Olson, E.N. "Correction of muscular dystrophies by CRISPR gene editing." Journal of Clinical Investigation, 130(6), 2766-2776 (2020). doi.org/10.1172/JCI136873

---

This article is for informational purposes only and does not constitute medical advice. Treatment decisions for Duchenne muscular dystrophy should be made in consultation with a qualified neuromuscular specialist. If your child has been diagnosed with DMD, contact the Parent Project Muscular Dystrophy (parentprojectmd.org) or the Muscular Dystrophy Association (mda.org) for support and resources.